Cubist Systematic Strategies LLC Invests $8.21 Million in Haemonetics Corporation $HAE

Key Points

• Cubist Systematic Strategies LLC has invested approximately $8.21 million in Haemonetics Corporation, acquiring 129,259 shares valued at 0.26% of the company.
• Institutional investors and hedge funds now own 99.67% of Haemonetics' stock, indicating a strong interest from large financial entities.
• Haemonetics recently reported earnings of $1.10 per share, surpassing estimates and setting FY 2026 guidance between $4.70 to $5.00 EPS.

Cubist Systematic Strategies LLC bought a new stake in shares of Haemonetics Corporation (NYSE:HAE - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 129,259 shares of the medical instruments supplier's stock, valued at approximately $8,214,000. Cubist Systematic Strategies LLC owned approximately 0.26% of Haemonetics as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of HAE. Quarry LP boosted its holdings in shares of Haemonetics by 63.4% during the 1st quarter. Quarry LP now owns 495 shares of the medical instruments supplier's stock valued at $31,000 after purchasing an additional 192 shares during the last quarter. University of Texas Texas AM Investment Management Co. bought a new position in shares of Haemonetics during the 1st quarter valued at about $65,000. KBC Group NV boosted its holdings in shares of Haemonetics by 19.9% during the 1st quarter. KBC Group NV now owns 2,417 shares of the medical instruments supplier's stock valued at $154,000 after purchasing an additional 401 shares during the last quarter. AlphaQuest LLC increased its holdings in shares of Haemonetics by 71.5% in the 1st quarter. AlphaQuest LLC now owns 3,140 shares of the medical instruments supplier's stock worth $200,000 after buying an additional 1,309 shares during the last quarter. Finally, Vise Technologies Inc. raised its position in shares of Haemonetics by 8.7% during the 4th quarter. Vise Technologies Inc. now owns 2,825 shares of the medical instruments supplier's stock valued at $221,000 after buying an additional 225 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company's stock.

Haemonetics Trading Up 0.5%

HAE stock traded up $0.26 during mid-day trading on Friday, reaching $54.34. The company had a trading volume of 627,638 shares, compared to its average volume of 1,077,717. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.72 and a quick ratio of 1.04. The company has a market capitalization of $2.62 billion, a PE ratio of 16.62, a price-to-earnings-growth ratio of 1.00 and a beta of 0.39. The firm has a 50 day moving average of $66.04 and a 200 day moving average of $65.76. Haemonetics Corporation has a 12 month low of $50.68 and a 12 month high of $94.99.

Haemonetics (NYSE:HAE - Get Free Report) last issued its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.10 EPS for the quarter, topping analysts' consensus estimates of $1.01 by $0.09. The business had revenue of $321.39 million for the quarter, compared to the consensus estimate of $305.12 million. Haemonetics had a net margin of 12.14% and a return on equity of 26.64%. The company's revenue for the quarter was down 4.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.02 EPS. Haemonetics has set its FY 2026 guidance at 4.700-5.00 EPS. On average, equities analysts predict that Haemonetics Corporation will post 4.55 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on HAE. JPMorgan Chase & Co. reissued a "neutral" rating and issued a $62.00 target price (down previously from $85.00) on shares of Haemonetics in a research note on Friday, August 8th. Needham & Company LLC reiterated a "buy" rating and set a $68.00 price target (down from $84.00) on shares of Haemonetics in a report on Thursday, August 7th. Robert W. Baird initiated coverage on shares of Haemonetics in a report on Thursday, June 26th. They set an "outperform" rating and a $87.00 price target on the stock. Baird R W upgraded shares of Haemonetics to a "strong-buy" rating in a report on Wednesday, June 25th. Finally, Citigroup upgraded shares of Haemonetics from a "neutral" rating to a "buy" rating and set a $90.00 price target on the stock in a report on Wednesday, July 9th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $85.18.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.